Showing results (41-50 of 155) with videos related to
Sort By:
Pageof 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2009
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtypeJacques Cadranel, Elisabeth Quoix, Laurence Baudrin, et al.Current Medical Research and Opinion|June 16, 2012
Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational studyAlain Vergnenegre, Egbert F Smit, Elisabeth Toy, et al.The European Respiratory Journal|October 24, 2015
Circulating free DNA concentration is an independent prognostic biomarker in lung cancerClaire Tissot, Anne-Claire Toffart, Stéphanie Villar, et al.Current Medical Research and Opinion|October 15, 2010
Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational studyDenis Moro-Sibilot, Alain Vergnenegre, Egbert F Smit, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Prognostic impact of paraneoplastic cushing's syndrome in small-cell lung cancerHélène Nagy-Mignotte, Oxana Shestaeva, Lucile Vignoud, et al.Respiratory Medicine and Research|June 6, 2024
Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancerDenis Moro-Sibilot, Lionel Falchero, Camille Ardin, et al.The Annals of Thoracic Surgery|February 6, 2018
Operation and Chemotherapy: Prognostic Factors for Lung Cancer With One Synchronous MetastasisAnne-Claire Toffart, Michaël Duruisseaux, Pierre-Yves Brichon, et al.The Journal of Pathology|May 21, 2011
Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinomaAmandine Hurbin, Marie Wislez, Benoît Busser, et al.Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017Mickaël Lattuca-Truc, Jean-François Timsit, Matteo Giaj Levra, et al.Lung Cancer (Amsterdam, Netherlands)|January 2, 2014
On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomasLénaïg Mescam-Mancini, Sylvie Lantuéjoul, Denis Moro-Sibilot, et al.Pageof 16